What Happened?
Bellaire, AB-based Bio-Path-Holdings Appointed Peter Nielsen as President, Chief Executive Officer
About the Company
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
About the Person
Peter Nielsen is President, Chief Executive Officer at Bio-Path Holdings. Previously, Peter held various senior HR leadership roles in the industry.
Info Source
News
Short Profile